Approved for use through 10/31/2002, OMB 0851-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collect form 1449A/PTO Cor

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 1 of 5

Confirmation Number	2148		
Application Number	09/966,447		
Filing Date	September 28, 2001		
First Named Inventor	David C. Lentz		
Group Art Unit	3773		
Examiner Name	Ryckman, M. K.		
Attorney Docket Number	CRD0957LISNP		

				U.S. PATENT DOCUMENTS		
Examiner Initials	Cite No.1	U.S. Patent Docum Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages of relevant figures appear
		3,929,992		Seghal, et al.	12-30-1975	
		4,350,160		Kolesov, et al.	09-21-1982	
		4,366,819		Kaster	01-04-1983	
		4,368,736		Kaster	01-18-1983	
		4,624,257		Berggren, et al.	11-25-1986	
		4,722,906		Guire	02-02-1988	
		4,917,090		Berggren, et al.	01-19-1988	
		4,917,091		Berggren, et al.	04-17-1988	
		5,229,172	А	Cahalan, et al.	07-20-1993	
		5,234,160		Lisiecki	08-10-1993	
		5,234,447	Α	Kaster, et al.	08-10-1993	
		5,308,641	А	Cahalan, et al.	05-03-1994	
		5,392,747		Williams, et al.	11-04-1992	
		5,415,938	А	Cahalan, et al.	05-16-1995	
		6,153,252		Hossainy	04-19-1999	

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not otation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Utilize clation designation number. See attached Kinds of U.S. Petert Documents. Enter Offse that issued the document, by the bevieter code (WIPO Standard ST.3). 4Fs Japanese patent documents, be indication of the year of the region of the Emperor must recrease the serial number of the patent document. 4Knd of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Application is to place a check mark here if English Imagage Translations is attached.

Burden Nov Setement: This form a estimated to take 20 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to correlate the form should be sent to the Chief Information Office. Us. Patent and Traislemak. Office. Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Va. 22131.4450

PTO/SB/08A (08-00)
Approved for use through 10/31/2002, OMB 0651-0031

Approval to use integral real states on the business of the patent and Trademark officer U.S. DePARTMENT OF COMMERCE.
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 5

Confirmation Number	2148			
Application Number	09/966,447			
Filing Date	September 28, 2001			
First Named Inventor	David C. Lentz			
Group Art Unit	3773			
Examiner Name	Ryckman, M. K.			
Attorney Docket Number	CRD0957HSNP			

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	T ²
Examiner's	Cite	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T*
Initials*	No.1	publisher, city and/or country where published	
		AJROLDI, G. et al., "Fluoroelastomers-Dependence of Relaxation Phenomena on	
		Compositions", POLYMER, 30, No. 12, (1989): 2180-2187.	
		BERK, B.C. et al., "Pharmacologic Roles of Heparin and Glucocorticoids to Prevent	
		Restenosis After Coronary Angioplasty", J. Am. Coll. Cardio. Vol. 17, No. 6, pp.	
		111B-117B (1991)	
		CAMPBELL and CAMPBELL, "Phenotypic Modulation of Smooth Muscle Cells in	
		Primary Culture", (Table of Contents), Chapter 2, Volume 1, pp. 39-52 (1985)	
		CAMPBELL and CAMPBELL "Cell Biology of Smooth Muscle in Culture:	
		Implications for Atherogenesis", Inter. Angio, 6, p. 73 (1987)",	
		CHANG, M.W. et al., "Adenovirus-mediated Over-expression of the Cyclin/Cyclin-	
		Dependent Kinase Inhibitor, p21 Inhibits Vascular Smooth Muscle Cell Proliferation	
		and Neointima Formation in the Rat Carotid Artery Model of Balloon Angioplasty", J.	
		Clin. Invest. Vol. 96, pp. 2260-2268 (1995)	
		CLOWES, A.W. et al., "Suppression by Heparin of Smooth Muscle Cell Proliferation	
		in Injured Arteries", Nature, Vol. 265, pp. 625-626 (1977)	
		CLOWES, A.W. et al., "Kinetics of Cellular Proliferation after Arterial Injury",	
		Laboratory Investigation, Vol. 52, No. 6, pp. 611-616 (1985)	
		CLOWES, A.W. et al., "Kinetics of Cellular Proliferation after Arterial Injury IV.	
		Heparin Inhibits Rat Smooth Muscle Mitogenesis and Migration", Circulation	
		Research, Vol. 58, No. 6, pp. 839-845 (1986)	
		CLOWES and SCHWARTZ, "Significance of Quiescent Smooth Muscle Migration in	
		the Injured Rat Carotid Artery", Cir. Res. 56: 139-145 (1985)	
		COLBURN, M.D. et al., "Dose Responsive Suppression of Myointimal Hyperplasia	
		by Dexamethasone", J. Vasc. Surg. Vol. 15, No. 3, pp. 510-518 (1992)	
		CURRIER, J.W. et al., "Colchicine Inhibits Restenosis After Iliac Angioplasty in the	
		Atherosclerotic Rabbit", Supplement II Circulation Vol. 80, No. 4, II-66 (1989)	
		EDELMAN, E., et al. "Pathobiologic Responses to Stenting", American Journal of	
	_	Cardiology Vol. 91, Issue 7, Suppl. 1 (April 1998) pp. 4E-6E	
		FARB, A. et al., "Vascular Smooth Muscle Cell Cytotoxicity and Sustained Inhibition	
		of Neointimal Formation by Fibroblast Growth Factor 2-Saporin Fusion Protein", Circ.	
		Res. Vol. 80, No. 4, pp. 542-550 (1997)	

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Burden Nov Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are equated to complete the form should be sent to the Chile Information Offset. U. S. Patent and Trademark Offset. Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandray, VA 22131-1450

PTO/SB/08A (08-00) Approved for use through 10/31/2002, OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 3 of 5

Confirmation Number	2148				
Application Number	09/966,447				
Filing Date	September 28, 2001				
First Named Inventor	David C. Lentz				
Group Art Unit	3773				
Examiner Name	Ryckman, M. K.				
Attorney Docket Number	CRD0957LISNP				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
FERNS, G.A. et al., "Inhibition of Neointimal Smooth Muscle Accumulation After Angioplasty by an Antibody to PDGF", Science, Vol. 253, pp. 1129-1132 (1991)	
FISCHMAN, D., et al. "A Randomized Comparison of Coronary-Stent Placement and Balloon Angioplasty in the Treatment of Coronary Artery Disease", The New England Journal of Medicine, Volume 331:496-501 (1994)	
FRANKLIN and FAXON S., et al. "Pharmacologic Prevention of Restenosis After Coronary Angioplasty: Review of the Randomized Clinical Trials", Coronary Artery Disease, Vol. 4, No. 3 (March 1993)	
FUKUYAMA J., et al., "Tranilast Suppresses the Vascular Intimal Hyperplasia After Balloon Injury in Rabbits Fed on a High-Cholesterol Diet", European Journal of Pharmacology 318, pp. 327-332 (1996)	
GUYTON, J.R. et al., "Inhibition of Rat Arterial Smooth Muscle Cell Proliferation by Heparin", Circulation Research, Vol. 46, No. 5, pp. 625-634 (1980)	
HANSON, S.R. et al., "Interruption of Acute Platelet-Dependent Thrombosis by the Synthetic Antithrombin p-Phenylalanyl-L-Prolyl-L-Arginyl Chloromethyl Ketone"; Roc. Natl. Acad. Sci. USA (5/1988) 85: 3184-3188.	
HANSSON, G.K., et al., "Interferon-y Inhibits Arterial Stenosis After Injury" Circulation, Vol. 84, No. 3, pp. 1266-1272 (1991)	
JONASSON, L. et al., "Cyclosporin A Inhibits Smooth Muscle Proliferation in the Vascular Response to Injury", Proc. Natl. Acad. Sci. USA Vol. 85, pp. 2303-2306, (1988)	
LANG R., et al. "Effects of Okadaic Acid and ATPyS on Cell Length and CA ^{2c} - Channel Currents Recorded in single Smooth Muscle Cells of the Guinea-Pig Taenia Caeci", Br. J. Pharmacol. 104, p. 331-336 (1991)	
LIU, M.W. et al., "Trapidil in Preventing Restenosis After Balloon Angioplasty in the Atherosclerotic Rabbit", Circ. Vol. 81, No. 3, pp. 1089-1093 (1990)	
LUNDERGAN, C.F. et al., "Peptide Inhibition of Myointimal Proliferation by Angiopeptin, a Somatostatin Analogue", JACC Vol. 17(Supp. B), No. 6. pp. 132B-136B (1991)	
MAJESKY, M.W. et al., "Heparin Regulates Smooth Muscle S Phase Entry in the Injured Rat Carotid Artery", Circ. Res. Vol. 61, No. 2, pp. 296-300 (1987)	
MAK and TOPOL, "Clinical Trials to Prevent Restenosis after Percutaneous Coronary Revascularization", Department of Cardiolog, Cleveland Clinical Foundation, Ohio p. 255 (1991)	
MARX, S.O., et al., "Rapamycin-FKBP Inhibits Cell Cycle Regulators of Proliferation in Vascular Smooth Muscle Cells", Circ. Res., Vol. 76, No. 3, pp. 412-417 (1995)	

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 2023.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA

22313-1450.

PTO/SB/08A (08-00)
Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Officer U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 4 of 5

a collection or information unless it displays a valid OMB control number.				
Confirmation Number	2148			
Application Number	09/966,447			
Filing Date	September 28, 2001			
First Named Inventor	David C. Lentz			
Group Art Unit	3773			
Examiner Name	Ryckman, M. K.			
Attornov Docket Number	CPD0957LISNID			

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		NEMECEK, G.M. et al., "Terbinafine Inhibits the Mitogenic Response to Platelet- Derived Growth Factor in Vitro and Neointimal Proliferation in Vivo", J. Pharmacol. Exp. Thera. Vol. 248, No. 3, pp.1167-1174 (1989)	
		OKADA, T. et al., Localized Release of Perivascular Heparin Inhibits Intimal Proliferation after Endothelial Injury without Systemic Anticoagulation, Neurosurgery, Vol. 25, No. 6, pp. 892-898 (1989)	
		POMPA, J., et al. "Clinical Trials of Restenosis After Coronary Angioplasty", American Heart Association, Circulation, (1991) 84:1426-1436	
		POWELL, J.S. et al., Inhibitors of Antiotensin-Converting Enzyme Prevent Myonitimal Proliferation After Vascular Injury*, Science, Vol. 245, pp. 186-188 (1989)	
		SERRUYS P., et al. "Evaluation of Ketanserin in the Prevention of Restenosis After Percutaneous Transluminal Coronary Angioplasty. A Multicenter Randomized Double-Blind Placebo-Controlled Trial", American Heart Association, Circulation, 88, p. 1588 (1993)	
		SERRUYS, P., et al. "A Comparison of Balloon-Expandable-Stent Implantation with Balloon Angioplasty in Patients with Coronary Artery Disease", New England Journal of Medicine, Volume 331:489-495 (1994)	
		SERRUYS, P., et al. "Heparin-Coated Palmaz-Schatz Stents in Human Coronary Arteries: Early Outcome of the Benestent-II Pilot Study", Circulation of the American Heart Association, Volume 93(3) p. 412-422 (1996)	
		SIMONS, M. et al., "Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation <i>in vivo</i> ", Nature, Vol. 359, pp. 67-70 (1992)	
		SNOW, A.D. et al., "Heparin Modulates the Composition of the Extracellular Matrix Domain Surrounding Arterial Smooth Muscle Cells", Vol. 137, No. 2, pp. 313-330, (1990)	
		SOLLOT, S.J. et al., "Taxol Inhibits Neointimal Smooth Muscle Cell Accumulation after Angioplasty in the Rat", J. Clinical Investigation, Inc. Vol. 95, pp. 1869-1876, (1995)	
		TANAKA, H., et al. "Sustained Activation of Vascular Cells and Leukocytes in the Rabbit Aorta After Balloon Injury", Circulation, Vol. 88, 1788-1803 (1993)	
Δ.		TARDIF, J-C., et al. "Probucol and Multivitamins in the Prevention of Restenosis After Coronary Angioplasty", New England Journal of Medicine, Volume 337:365- 372 (1997)	

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not obtains in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

I Urique chation designation number. See attached Kinds of U.S. Patient Documents. Either Office that issued the document by the two-letter code (WIPO Standard ST.3), 4-67 bagances patent documents, the indication of the year of the regner or must precede the explanation of the patient document. 4-Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 4-Applicating to place a check mark here of English illinguage Transfation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chile Homanistion Office. U. S. Patent and Trademark Office. Washington, Dc 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22131-1450

Approved for use through 10/31/2002, OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number orm 1449A/PTO Confirmation Number 2148

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 5 of 5

Confirmation Number	2148			
Application Number	09/966,447			
Filing Date	September 28, 2001			
First Named Inventor	David C. Lentz			
Group Art Unit	3773			
Examiner Name	Ryckman, M. K.			
Attorney Docket Number	CRD0957USNP			

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
TEIRSTEIN, P., et al. "Catheter-Based Radiotherapy to Inhibit Restenosis After Coronary Stending", The New England Journal of Medicine, Volume 336 p. 1697 (June 1997)	
WEINBERGER, J. et al., "Intracoronary Irradiation: Dose Response for the Prevention of Restenosis in Swine", Int. J. Radiation Onc. Biol. Phys. Vol. 36, No. 4, pp. 767-775 (1996)	
WILEY and SONS, "Fluoro Carbon Elastomers, Modern Fluoropolymers", Wiley Series in Polymer Science, p. 71-90 (1997)	
YOKOI H., et al. "Effectiveness of an Antioxidant in Preventing Restenosis After Percutaneous Transluminal Coronary Angioplasty: The Probucol Angioplasty Restenosis Trial", JACC Vol. 30, No. 4 p. 855-862 (1997)	

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

I Unique citation designation number, 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office. Washindton, D. C 20231.

Trademark Unice, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

xaminer ignature				
 		T 14-100 to 1	0	a version and

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, Include copy of this form with next communication to applicant.

I Unique clation designation number. See attached Kinds of U.S. Patient Dozuments. Either Office that issued the document, by the two-letter code (WIPD Standard ST.3), 4-Fo. Japanese patient dozuments, the indication of the year of the region of the Emperor must preade the serial number of the patient dozument. 4-Kind of dozument by the appropriate symbols as indicated on the dozument under WIPD Standard ST. 16 if possible. 4-Application is to place a check mark here if Emiliphi fanousage Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Child Information Office. U. S. Patent and Trademark Office. Washington, Dc 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450